Evidence map›Paper›PMID 40751464›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2025

Long-Term Electrocardiographic Changes Following Renal Denervation-Left Ventricular Mass and Arrhythmia Burden.

Gianni Sesa-Ashton, Janis M Nolde, Bart Tang, Revathy Carnagarin, Elisabeth A Lambert, Gavin W Lambert, Marcio G Kiuchi, Vaughan G Macefield, Antony Walton, Carl J Schultz and 3 more

Abstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gianni Sesa-AshtonBaker Heart and Diabetes Institute, Melbourne, Australia.
Janis M NoldeDobney Hypertension Centre, Medical School - Royal Perth Hospital Unit and RPH Research Foundation, The University of Western Australia, Perth, Western Australia, Australia.ORCID 0000-0001-6864-8514
Bart TangDobney Hypertension Centre, Medical School - Royal Perth Hospital Unit and RPH Research Foundation, The University of Western Australia, Perth, Western Australia, Australia.
Revathy CarnagarinDobney Hypertension Centre, Medical School - Royal Perth Hospital Unit and RPH Research Foundation, The University of Western Australia, Perth, Western Australia, Australia.
Elisabeth A LambertSchool of Health Sciences and Iverson Health Innovation Research Institute, Swinburne University of Technology, Melbourne, Australia.
Gavin W LambertSchool of Health Sciences and Iverson Health Innovation Research Institute, Swinburne University of Technology, Melbourne, Australia.ORCID 0000-0003-0315-645X
Marcio G KiuchiDobney Hypertension Centre, Medical School - Royal Perth Hospital Unit and RPH Research Foundation, The University of Western Australia, Perth, Western Australia, Australia.
Vaughan G MacefieldDepartment of Neuroscience, Monash School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Antony WaltonDepartment of Cardiology, Alfred Health, Melbourne, Victoria, Australia.
Carl J SchultzDepartment of Cardiology, Royal Perth Hospital, Perth, Australia.
Sharad ShettyDepartment of Cardiology, Fiona Stanley Hospital, Perth, Australia.
Murray D EslerBaker Heart and Diabetes Institute, Melbourne, Australia.
Markus P SchlaichBaker Heart and Diabetes Institute, Melbourne, Australia.ORCID 0000-0002-1765-0195

Funding

Medtronic Europe
6 · The paper itself

Abstract

Renal denervation (RDN) is an adjunct therapy for resistant hypertension, reducing blood pressure (BP) by inhibiting both afferent sensory and efferent sympathetic renal nerve activity. The resulting reduction in central sympathetic outflow including that directed toward the heart may beneficially impact cardiac remodeling, left ventricular hypertrophy (LVH) and atrial fibrillation (AF). RDN has been shown to reduce left ventricular mass and AF burden but long-term data is sparse. Forty patients (72.5% male, 69.2 ± 9.6 years) underwent 12-lead ECG at baseline prior to RDN and at a mean long-term follow-up (LTFU) of 8.3 ± 0.9 years post-intervention. A 24-h ambulatory blood pressure monitor (ABPM) was obtained at both time points. Cornell voltage indices were calculated at baseline and LTFU, then converted to left ventricular mass based on validated formulae accounting for sex. ECGs underwent cardiologist review for determination of AF at both time-points. There was no difference in Cornell voltages or left ventricular mass index (LVMI) between baseline and long-term follow-up in neither males (p = 0.89) nor females (p = 0.91). BP lowering at LTFU was correlated with a more pronounced reduction in LVMI (r = 0.50, p = 0.0011) No change was observed in the incidence of atrial fibrillation between baseline or long-term follow-up (p = 0.99). There was no reduction in mean Cornell voltage or LVMI across the cohort between baseline and long-term follow-up. However, changes in ambulatory systolic BP correlated with reduction in LVMI suggestive of an RDN-induced BP dependent long-term reduction in LVMI out to eight years post-RDN.

Indexed as

ElectrocardiographyHypertensionHypertrophy, Left VentricularKidneySympathectomyAgedAtrial FibrillationBlood PressureBlood Pressure Monitoring, AmbulatoryFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedTreatment OutcomeECG changesleft ventricular hypertrophyleft ventricular massrenal denervation

Identifiers

PMID40751464
PMCPMC12317330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.